Company news
Heron Therapeutics, Inc. (NASDAQ:HRTX) news
Every Heron Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
July 27, 2026
U.S. District Court Issues Decision Regarding CINVANTI® Patents
June 2, 2026
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
May 11, 2026
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
April 27, 2026
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
February 26, 2026
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
February 17, 2026
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
January 9, 2026
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for ...
December 4, 2025
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
November 4, 2025
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
October 29, 2025
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
August 15, 2025
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
August 8, 2025
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
August 8, 2025
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
August 8, 2025
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
July 28, 2025
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
May 6, 2025
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
May 6, 2025
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
April 28, 2025
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
April 22, 2025
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
February 27, 2025
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
February 13, 2025
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
December 23, 2024
U.S. District Court Upholds Validity of CINVANTI® Patents
December 3, 2024
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
November 12, 2024
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
November 4, 2024
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
October 29, 2024
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Short...
October 10, 2024
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
September 25, 2024
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
September 3, 2024
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
August 6, 2024
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
July 30, 2024
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief...
July 15, 2024
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
July 2, 2024
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
May 29, 2024
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
May 7, 2024
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
April 24, 2024
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
April 11, 2024
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
March 12, 2024
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
February 28, 2024
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
January 23, 2024
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-...
January 7, 2024
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
November 14, 2023
Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
November 7, 2023
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
August 14, 2023
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
August 7, 2023
Heron Therapeutics Announces $30 Million Private Placement Financing
July 24, 2023
Heron Therapeutics Announces Cost Reduction Plan and Restructuring
July 24, 2023
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
June 23, 2023